Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

@article{Sax2015TenofovirAV,
  title={Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials},
  author={Paul E Sax and David Alain Wohl and Michael T. Yin and Frank A. Post and Edwin Dejesus and Michael S Saag and AntonL. Pozniak and Melanie A. Thompson and Daniel Podzamczer and Jean Michel Molina and Shinichi Oka and Ellen G. Koenig and Benoit Trottier and Jaime F Andrade-Villanueva and Gordon Crofoot and Joseph M. Custodio and Andrew D Plummer and Lijie Zhong and Huyen L Cao and Hal David Martin and Christian Callebaut and A. S. K. Cheng and Marshall W. Fordyce and S. Mccallister},
  journal={The Lancet},
  year={2015},
  volume={385},
  pages={2606-2615}
}
BACKGROUND Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug with a 90% reduction in plasma tenofovir concentrations. Tenofovir alafenamide-containing regimens can have improved renal and bone safety compared with tenofovir disoproxil fumarate-containing regimens. METHODS In these two controlled, double-blind phase 3 studies, we recruited treatment-naive HIV-infected patients… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 135 CITATIONS, ESTIMATED 51% COVERAGE

277 Citations

05010020152016201720182019
Citations per Year
Semantic Scholar estimates that this publication has 277 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 26 REFERENCES

Similar Papers

Loading similar papers…